Sanjivani Paranteral Limited (BOM:531569)
192.35
-3.25 (-1.66%)
At close: Aug 17, 2026
Sanjivani Paranteral Revenue
Sanjivani Paranteral had revenue of 239.90M INR in the quarter ending June 30, 2026, with 34.08% growth. This brings the company's revenue in the last twelve months to 747.28M, up 4.44% year-over-year. In the fiscal year ending March 31, 2026, Sanjivani Paranteral had annual revenue of 686.66M, down -2.04%.
Revenue (ttm)
747.28M
Revenue Growth
+4.44%
P/S Ratio
3.16
Revenue / Employee
18.68M
Employees
40
Market Cap
2.36B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 686.66M | -14.33M | -2.04% |
| Mar 31, 2025 | 700.99M | 156.88M | 28.83% |
| Mar 31, 2024 | 544.11M | 189.19M | 53.31% |
| Mar 31, 2023 | 354.92M | 48.79M | 15.94% |
| Mar 31, 2022 | 306.13M | 55.13M | 21.96% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Bilcare | 7.34B |
| Medicamen Biotech | 2.06B |
| Sat Kartar Life | 2.01B |
| Everest Organics | 1.92B |
| Gennex Laboratories | 1.78B |
| Astonea Labs | 1.48B |
| Oxygenta Pharmaceutical | 1.35B |
| Kerala Ayurveda | 1.27B |